Xeris Pharmaceuticals (NASDAQ:XERS) announces that Gvoke HypoPen (glucagon injection) is now available by prescription in the U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.
Gvoke HypoPen is available in two doses: 0.5 mg/0.1 mL for children (who weigh less than 100 pounds) and 1 mg/0.2 mL for adolescents and adults (who weigh 100 pounds or greater).
For a limited time, eligible commercially-insured patients may pay $0 for a two-pack of Gvoke HypoPen by using the Gvoke copay savings card.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.